{"commentary":{"count":4,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT06712316","nct_id":"NCT06712316","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06712316. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Substudy A Phase 2 (Arm 1) - Pumitamig Dose 1 + Carboplatin + Pemetrexed","type":"EXPERIMENTAL"},{"description":null,"label":"Substudy A Phase 2 (Arm 2) - Pumitamig Dose 2 + Carboplatin + Pemetrexed","type":"EXPERIMENTAL"},{"description":null,"label":"Substudy A Phase 2 (Arm 1A - China only) - Pumitamig Dose 3 + Carboplatin + Pemetrexed","type":"EXPERIMENTAL"},{"description":null,"label":"Substudy A Phase 3 (Arm 3) - Pumitamig Dose 3 + Carboplatin + Pemetrexed","type":"EXPERIMENTAL"},{"description":null,"label":"Substudy A Phase 3 (Arm 4) - Pembrolizumab + Carboplatin + Pemetrexed","type":"ACTIVE_COMPARATOR"},{"description":null,"label":"Substudy B Phase 2 (Arm 1) - Pumitamig Dose 1 + Carboplatin + Paclitaxel","type":"EXPERIMENTAL"},{"description":null,"label":"Substudy B Phase 2 (Arm 2) - Pumitamig Dose 2 + Carboplatin + Paclitaxel","type":"EXPERIMENTAL"},{"description":null,"label":"Substudy B Phase 2 (Arm 1A, China only) - Pumitamig Dose 3 + Carboplatin + Paclitaxel","type":"EXPERIMENTAL"},{"description":null,"label":"Substudy B Phase 3 (Arm 3) - Pumitamig Dose 3 + Carboplatin + Paclitaxel","type":"EXPERIMENTAL"},{"description":null,"label":"Substudy B Phase 3 (Arm 4) - Pembrolizumab + Carboplatin + Paclitaxel","type":"ACTIVE_COMPARATOR"}],"collaborators":["Bristol-Myers Squibb"],"completion_date":{"date":"2031-12","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":1580,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Pumitamig","type":"DRUG"},{"name":"Pembrolizumab","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Pemetrexed","type":"DRUG"},{"name":"Paclitaxel","type":"DRUG"}],"last_update":"2026-09-22","lead_sponsor":"BioNTech SE","official_title":"A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer","overall_status":"RECRUITING","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2029-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase 2 - Occurrence of treatment-emergent adverse events (TEAE) (including Grade ≥3), adverse events of special interest (AESIs), treatment-related TEAEs, treatment-emergent serious adverse events (SAE), and treatment-related treatment emergent SAEs","timeFrame":"From the first dose of the investigational medicinal product (IMP) to the 90-day Follow-Up Visit"},{"measure":"Phase 2 - Occurrence of dose interruption, reduction, and discontinuation of IMP due to TEAEs (including related TEAEs)","timeFrame":"From the first dose of IMP to the 90-day Follow-Up Visit"},{"measure":"Phase 2 - Objective response rate (ORR)","timeFrame":"Up to approximately 2 years"},{"measure":"Phase 2 - Best percentage change from baseline in tumor size","timeFrame":"Up to approximately 2 years"},{"measure":"Phase 3 - Progression free survival (PFS) assessed by BICR","timeFrame":"Up to approximately 5 years"}],"references":[],"start_date":{"date":"2025-01-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer","url":"https://clinicaltrials.gov/study/NCT06712316"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06712316"}